QIAGEN expands presence in Thailand to serve life sciences

Food and Healthcare Press Releases Friday June 16, 2017 10:46
Bangkok--16 Jun--ABM
Opens Bangkok office and launches collaborations for malaria and cancer research

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion in Thailand and opened an office in Bangkok to enhance relationships with life science researchers and healthcare providers in the growing market. QIAGEN also announced two new collaborations in Thailand: a molecular techniques center established with the faculty for tropical medicine at Mahidol University and a collaboration with Ramathibodi Hospital to study genomic insights from next-generation sequencing (NGS).

"We are pleased to expand our commitment to the people of Thailand, where we have built relationships with medical institutions and the government for more than 16 years. As we open our new Bangkok office, we are also introducing new collaborations with two of the country's leading medical institutions," said Mr. William Lin, Director of Commercial Operations for QIAGEN Thailand. "We look forward to providing Thai scientists and healthcare providers with innovative Sample to Insight solutions for molecular testing, including our NGS solutions, as we seek to make improvements in life possible."

The collaboration with Mahidol University has established the QIAGEN–TropMed Center for Molecular Techniques in conjunction with the Faculty of Tropical Medicine to support research using molecular biology techniques.

"We are happy to join with QIAGEN in creating the TropMed Center for Molecular Techniques to bring the benefits of genomic insights to research on malaria and other diseases. Our partnership will demonstrate the potential of academic-industry collaboration, as well as educate the younger generation in techniques of molecular biology," said Dr. Wang Nguitragool, Assistant Professor, Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine of Mahidol University.

QIAGEN has joined with the Medical Genomic Center at Ramathibodi Hospital in Bangkok to help guide personalized healthcare treatment decisions using QIAGEN NGS solutions.

"QIAGEN NGS solutions, highly sensitive sequencing analyzes liquid biopsies or tissue samples to identify genetic mutations and enable doctors to select the best possible treatment. We expect this collaboration to have significant benefits for cancer patients," said Dr. Thanyanan Reungwetwattana, Assistant Professor, Division of Medical Oncology, Department of Medicine, Faculty of Medicine of Ramathibodi Hospital.

The expansion in Thailand supports QIAGEN's strategy of investing in emerging markets, where the use of advanced molecular technologies for medical care and research is growing rapidly. "The German-Thai Chamber of Commerce is proud to see another established German brand set root in Thailand. I am very happy to see that QIAGEN is expanding to Thailand because they bring their expertise to the local science community and contribute to the improvement of the life of the Thai people," said Dr. Roland Wein, Executive Director, German-Thai Chamber of Commerce. In 2016, QIAGEN sales in its top seven emerging markets grew 19% and contributed 16% of total net sales of $1.34 billion.


Latest Press Release

ESMO Publishes New Position Paper on Supportive and Palliative Care

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757 ], calling attention to the evolving and growing gap between the needs of cancer...

Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

The medical device company is transforming neurological treatments through its non-invasive focused ultrasound applications Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies,...

MediaTek Sensio: New Biosensor Solution Brings Health Monitoring to Smartphones

MediaTek Inc. today unveiled MediaTek Sensio(TM), the first 6-in-1 smartphone biosensor module. MediaTek Sensio is a powerful advanced health monitoring solution which makes it easy to track heart rate information, blood pressure trends, peripheral...

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Related Topics